AL3818: Nivolumab in combination with anlotinib achieved remarkable efficacy in a patient with driver-negative lung squamous cell carcinoma and PS of 4

Bezafibrate : NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)α- mediated cardiovascular effects